Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-04-02
2010-02-23
Qazi, Sabiha N. (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S026000, C536S005000, C536S006000
Reexamination Certificate
active
07666846
ABSTRACT:
Unique compounds that can be used for inducing an immune response toBorrelia burgdorferiin a subject by administering a therapeutically effective amount of the glycolipid to the subject. Such administration is particularly useful for preventing or treating Lyme disease in a subject. The compounds(s), and therapeutically acceptable salts thereof, may be formulated into pharmaceutical or immunogenic compositions.
REFERENCES:
patent: 3966918 (1976-06-01), Kawamata et al.
patent: 4031303 (1977-06-01), Murai et al.
patent: 4189471 (1980-02-01), Ponpipom et al.
patent: 4229441 (1980-10-01), Bugianesi et al.
patent: 4254111 (1981-03-01), Pegel et al.
patent: 4721617 (1988-01-01), Johnson
patent: 6203798 (2001-03-01), Bergstrom et al.
patent: 0 023 865 (1981-02-01), None
patent: 08-070885 (1996-03-01), None
Alving et al., “Antibodies to Cholesterol, Cholesterol Conjugates and Liposomes: Implications for Atherosclerosis and Autoimmunity,”Crit Rev. Immunol. 10:441-453, 1991.
Anspach, “Endotoxin removal by affinity sorbents,”J. Biochem. Biophys. Methods49:665-681, 2001.
Asbrink et al., “The Spirochetal Etiology of Acrodermatitis chronica atrophicans Herxheimer,”Acta Derm Venerol(Stockh) 64:506-512, 1984.
Barbour et al., “Antibodies of Patients with Lyme Disease to Components of theIxodes damminiSpirochete,”The Journal of Clinical Investigation72:504-515, 1983.
Barbour et al., “ABorrelia-Specific Monoclonal Antibody Binds to a Flagellar Epitope,”Infection and Immunity52(5):549-554, 1986.
Barbour et al., “Biology ofBorreliaSpecies,”Microbiological Reviews50(4):381-400, 1986.
Beck et al., “Chemical and Biological Characterization of a Lipopolysaccharide Extracted From the Lyme Disease Spirochete (Borrelia burgdorferi),”The Journal of Infectious Diseases152(1):108-117, 1985.
Beck et al., “Isolation, Preliminary Chemical Characterization, and Biological Activity ofBorrelia burgdorferiPeptidoglycan,”Biochemical and Biophysical Research Communications167(1):89-95, 1990.
Ben-Menachem et al., “Antibody response to MfGL-II, a phosphocholine-containing major lipid ofMycoplasma fermentansmembranes,”FEMS Microbiology Letters154:363-369, 1997.
Bligh et al., “A Rapid Method of Total Lipid Extraction and Purification,”Canadian Journal of Biochemistry and Physiology37(8):911-917, 1959.
Bock et al., “A Study of13CH Coupling Constants in Pentopyranoses and Some of their Derivatives,”Acta Chemica Scandinavica B29(2):258-264, 1975.
Craft et al., “Antigens ofBorrelia burgdorferiRecognized during Lyme Disease,”J. Clin. Invest. 78:934-939, 1986.
Dell et al., “F.A.B.-Mass Spectrometry of Carbohydrates,”Advances in Carbohydrate Chemistry and Biochemistry45:19-72, 1987.
Habicht et al., “Lyme Disease Spirochetes Induce Human and Murine Interleukin 1 Production,”Journal of Immunology134(5):3147-3154, 1985.
Halter et al., “Lipooligosaccharides fromTreponema hyodysenteriaeandTreponema innocens,” Infection and Immunity56(12):3152-3156, 1988.
Hirai et al., “Unique Cholesteryl Glucosides inHelicobacter pylori: Composition and Structural Analysis,”Journal of Bacteriology177(18):5327-5333, 1995.
Honarvar et al., “A 14,000 MW lipoprotein and a clycolipid-like structure ofBorrelia burgdorferiinduce proliferation and immunoglobulin production in mouse B cells at high frequencies,”Immunology82:389-396, 1994.
Lathrop et al., “Adverse event reports following vaccination for Lyme disease: Dec. 1998-Jul. 2000,”Vaccine20:1603-1608, 2002.
Livermore et al., “Lipid Metabolism ofBorrelia hermsi,” Infection and Immunity20(1):215-220, 1978.
Mayberry et al., “Structures and Properties of Acyl Diglucosylcholesterol and Galactofuranosyl Diacylgylcerol fromAcholeplasma axanthum,” Biochemica et Biophysica Acta752:434-443, 1983.
Orloski et al., “Surveillance for Lyme Disease—United States, 1992-1998,”MMWR Morbidity and Mortality Weekly Report CDC Surveillance Summary49(SS-3):1-30, 2000.
Paściak et al., “Structure of the major glycolipid fromRothia dentocariosa,” Biochimica et Biophysica Acta1594:199-205, 2002.
Radolf et al., “Characterization of Outer Membranes Isolated fromBorrelia burgdorferi, the Lyme Disease Spirochete,”Infection and Immunity63(6):2154-2163, 1995.
Rahn, “Vaccine Recommendations: Challenges and Controversies,”Infectious Disease Clinics of North America15(1):1-15, 2001.
Rasley et al., “Borrelia burgdorferiinduces inflammatory mediator production by murine microglia,”Journal of Neuroimmunology130:22-31, 2002.
Razin, “Cholesterol Incorporation into Bacterial Membranes,”Journal of Bacteriology124(1):570-572, 1975.
Reich et al., “Nuclear Magnetic Resonance Spectrocopy. Carbon-13 Spectra of Steroids,”Journal of the American Chemical Society91(26):7445-7454, 1969.
Roth et al., “The Quantitative Determination of Galactose—An Enzymic Method Using Galactose Oxidase, with Applications to Blood and Other Biological Fluids,”Analytical Biochemistry10:32-52, 1965.
Rottem, “Sterols and Acylated Proteins in Mycoplasmas,”Biochemical and Biophysical Research Communications292(5):1289-1292, 2002.
Sadziene et al., “Experimental Immunization against Lyme Borreliosis with Recombinant Osp Proteins: An Overview,”Infection24(2):195-202, 1996.
Sawardeker et al., “Quantitative Determination of Monosaccharides as Their Alditol Acetates by Gas Liquid Chromatography,”Analytical Chemistry37:1602-1604, 1965.
Srimal et al., “Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A,”Biochem. J.315 679-686, 1996.
Steere et al., “Chronic Lyme Arthritis. Clinical and Immunogenetic Differentiation from Rheumatoid Arthritis,”Annals of Internal Medicine90:896-901, 1979.
Steere et al., “Lyme Carditis: Cardiac Abnormalities of Lyme Disease,”Annals of Internal Medicine93(Part1):8-16, 1980.
Steere et al., “The Early Clinical Manifestations of Lyme Disease,”Annals of Internal Medicine99:76-82, 1983.
Steere et al., “The Spirochetal Etiology of Lyme Disease,”The New England Journal of Medicine308(13):733-740, 1983.
Steere, “Lyme Disease,”The New England Journal of Medicine345(2):115-125, 2001.
Takayama et al., “Absence of Lipopolysaccharide in the Lyme Disease Spirochete,Borrelia burgdorferi,” Infection and Immunity55(9):2311-2313, 1987.
Vinh et al., “Characterization and Taxonomic Significance of Lipopolysacharides ofLeptospira interrogansSerovarhardjo,” Journal of General Microbiology135:2663-2673, 1989.
Zähringer et al., “Primary Structure of a New Phosphocholine-containing Glycoglycerolipid ofMycoplasma fermentans,” The Journal of Biological Chemistry272(42):26262-26270, 1997.
Ben-Menachem et al., “A newly discovered cholesteryl galactoside fromBorrelia burgdorferi,” PNAS 100(13):7913-7918, Jun. 2003.
Cinco et al., “Evidence for (lipo) oligosaccharides inBorrelia burgdorferiand their serological specificity,”FEMS Microbiology Immunology76:33-38, 1991.
Eiffert et al., “Identification of an immunoreactive non-proteinaleous component inBorrelia burgdorferi,” Med Microbiol Immunol180:229-237, 1991.
Hossain et al., “Structural analysis of glycolipids fromBorrelia burgdorferi,” Biochimie83:683-692, 2001.
Schröder et al., “Acylated Cholesteryl Galactoside as a Novel Immunogenic Motif inBorrelia burgdorferi Sensu Stricto,” The Journal of Biological Chemistry278(36):33645-33653 (published electronically Jun. 2003).
Wheeler et al., “Nonprotein Antigens ofBorrelia burgdorferi,” The Journal of Infectious Diseases, 167:665-674, 1993.
Internatio
Ben-Menachem Gil
Kubler-Kielb Joanna
Pozsgay Vince
Robbins John B.
Schneerson Rachel
Klarquist & Sparkman, LLP
Qazi Sabiha N.
The United States of America as represented by the Department of
LandOfFree
Cholesterol-containing compounds and their use as immunogens... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cholesterol-containing compounds and their use as immunogens..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cholesterol-containing compounds and their use as immunogens... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171057